BPC-157: A Deep Animal Record, A Thin Human File

The short version

BPC-157 stands for Body Protection Compound 157. It is a fifteen-amino-acid synthetic peptide copied from part of a protective protein found in human stomach juice. In animal studies — overwhelmingly rats — it appears to speed healing in tendon, gut, muscle, and nerve. The most consistent explanation in the literature is that it stimulates new blood-vessel growth into injured tissue, which restores the oxygen and nutrients that repair needs ^[4].

The honest line: almost everything known about BPC-157 comes from animals. As of 2025 reviews, only three small human pilot studies exist, and there are no large, rigorous controlled trials ^[2]. BPC-157 is not approved as a medicine anywhere. It is banned in sport. Common online claims about weight loss, muscle building, and testosterone are not supported by the published science and should be treated skeptically ^[2]. This page summarizes what was studied. It is not advice and lists no human dose.

What it is

BPC-157 is classified as a stable gastric pentadecapeptide. "Pentadecapeptide" means a fifteen-amino-acid chain; "stable gastric" because it is derived from a cytoprotective protein in gastric juice and resists breakdown there. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It carries research designations PL 14736, PLD-116, PL-10, and PL-10. Molecular formula: C62H98N16O22.

It is a synthetic compound — not extracted from any natural source — and it is not an approved drug. Pharmacokinetic work in rats and dogs characterized it as having a short elimination half-life (under 30 minutes), modest intramuscular bioavailability (approximately 14-19% in rats, 45-51% in dogs), and rapid metabolism into small peptide fragments that re-enter normal amino-acid pathways ^[3]. The intact peptide does not linger in the bloodstream.

How it works

The best-characterized pathway is angiogenesis — new blood-vessel growth. In a 2017 study spanning a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells, BPC-157 up-regulated the expression of VEGFR2 (a key vessel-growth receptor) and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS signaling pathway; blocking endocytosis blocked the effect ^[4]. Blood-flow recovery in an ischemic muscle model was accelerated ^[4].

Additional reported pathways include:

• FAK-paxillin complex — a cell-migration route that helps cells move into a wound site
• Growth hormone receptor sensitization in tendon fibroblast cells
• Nitric-oxide system modulation — connected to the VEGFR2-eNOS arm above
• Neurotransmitter system effects — serotonin and dopamine modulation noted in preclinical work

The peptide does not appear to hit a single target. Its animal-model effects span several repair-related pathways, with the angiogenesis story most consistently supported by independent data ^[4].

What the research shows

Gastric cytoprotection. The original rationale for BPC-157 was gut protection. In Wistar rats, it reduced gastric ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric; ulcer-formation inhibition ratios ran roughly 46-66% at higher doses, with accelerated epithelial rebuilding and granulation-tissue formation ^[5].

Angiogenesis mechanism. The 2017 work by Hsieh et al. established the VEGFR2-Akt-eNOS pathway as the primary vascular mechanism in endothelial cell culture, chick membrane, and rat ischemia models ^[4]. This is the most independently replicated mechanistic finding.

Pharmacokinetics. The first formal ADME characterization (rats and beagle dogs, 2022) found linear pharmacokinetics, a very short elimination half-life, modest IM bioavailability, and rapid breakdown to peptide fragments entering amino-acid metabolism ^[3]. These data help model tissue exposure but do not establish human dosing.

Human evidence. A 2025 first-in-human intravenous safety pilot administered BPC-157 up to 20 mg to two healthy adults; no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[1]. Two people — a safety signal, not an efficacy finding. A 2025 narrative review counts only three pilot studies total, confirms no rigorous large-scale controlled trials exist, and recommends treating BPC-157 as investigational with caution ^[2].

Reported effects, cautions & safety

The safety picture in the thin human dataset and the animal record is generally reassuring — but "as far as it goes" is the key phrase. Long-term, large-sample human safety data do not exist, so the true benefit-risk balance in people is unknown ^[2].

Community-reported effects (anecdotal, not clinical evidence): In research-use communities, BPC-157 is tried most often for stubborn tendon, ligament, and joint injuries. Very commonly reported benefits include faster recovery from those injuries and reduced joint stiffness. Frequently reported: improved digestive or gut symptoms, reduced bloating and cramping. Occasionally reported benefits include faster skin and wound healing, and improved sleep or mood — though commentators note the last two could easily reflect less pain or gut discomfort rather than a direct effect. Very commonly reported adverse effects include brief injection-site stinging and a small redness or bump. Frequently reported: mild nausea or loose stools, especially in the first few days. Occasionally reported: mild fatigue in the first week, headache, dizziness shortly after injecting, and transient flushing. Rarely: heart palpitations, which commentators recommend investigating promptly. All of these are anecdotal, unverified self-reports from research-use communities — not findings from controlled clinical studies.

Cautions from the literature:

• Single-group dominance. A large share of the foundational BPC-157 literature originates from one research group. Newer reviewers explicitly flag limited independent replication ^[2].
• Pro-angiogenic mechanism. Because the peptide's repair effects are tied to vessel growth via VEGFR2, there is a theoretical concern for individuals with active or suspected cancers, which also depend on angiogenesis for growth — though this is mechanistic reasoning, not a human finding ^[4].
• Serotonin interactions. Preclinical work shows BPC-157 alters brain serotonin activity; there is a theoretical, animal-based concern about combining it with serotonin-raising medicines.
• Banned in sport. WADA prohibits BPC-157 at all times under the S0 non-approved substances category.
• Unregulated supply. Not an approved drug; sold for laboratory research use only. Identity and purity of any given product are unverified outside formal study conditions.

Where it fits in repair and metabolic research

Among this desk's three compounds, BPC-157 occupies the tissue repair end of the spectrum. Its animal evidence spans tendon, gut, muscle, and nerve, unified by the angiogenesis mechanism. Its evidence base is the widest preclinically but thinnest in humans — three small pilots, no large trials ^[2]. Read alongside retatrutide, which addresses metabolic function via three receptor systems simultaneously, and tesamorelin, which carries the only regulatory approval across the three, BPC-157 represents the preclinical frontier of this field: a strong and consistent animal signal that has barely entered controlled human study. See the comparison page for a side-by-side view.